Phuturdex › Diseases › Digestive system neoplasm
Drugs in development · updated 30 October 2026
Digestive system neoplasm: drugs in development
As of 30 October 2026 there are 24 active clinical trials (recruiting or ongoing, phases I–III) on 37 drugs for digestive system neoplasm. 19 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PF-08634404 | III | 1 | NCT07222800 |
| CamrelizumabCarrelizumab, Carilizumab | II | 2 | NCT05624099 |
| AnlotinibAL3818, Anrotinib | II | 1 | NCT05252078 |
| ApatinibRivoceranib | II | 1 | NCT06099821 |
| Arfolitixorin | I–II | 1 | NCT06922383 |
| BenmelstobartTQB2450 | II | 1 | NCT05252078 |
| BL-M08D1 | I–II | 1 | NCT07780318 |
| DB-1324 | I–II | 1 | NCT07263594 |
| KN046 | II | 1 | NCT06099821 |
| KQB198 | II | 1 | NCT07406633 |
| SKB571 | II | 1 | NCT07564466 |
| BL-ARC002 | I | 1 | NCT07763652 |
| BL-M09D1 | I | 1 | NCT06954077 |
| BL-M24D1 | I | 1 | NCT07279428 |
| E7386 | I | 1 | NCT03833700 |
| GNC-077 | I | 1 | NCT06755242 |
| INCB0123667 | I | 1 | NCT05238922 |
| Izalontamab brengitecanBL-B01D1, BMS-986507 | I | 1 | NCT05262491 |
| SI-B036 | I | 1 | NCT07678970 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Bevacizumabavastin, MVASI | III | 5 | NCT07222800 |
| IrinotecanOnivyde, CPT-11 | III | 2 | NCT04607421 |
| CapecitabineXeloda, Capectitabine Tablets | III | 1 | NCT04607421 |
| CetuximabErbitux | III | 1 | NCT04607421 |
| EncorafenibBraftovi® | III | 1 | NCT04607421 |
| LeucovorinFolinic acid, l-leucovorin | III | 1 | NCT04607421 |
| OxaliplatinOxaliplatine, Oxaliplain | III | 1 | NCT04607421 |
| PaclitaxelTaxol, Paxlitaxel | II | 2 | NCT05624099 |
| All-trans retinoic acidATRA, Tretinoin | II | 1 | NCT07586813 |
| AtezolizumabTecentriq, MPDL3280A | II | 1 | NCT06096779 |
| ImatinibSTI571, Imkeldi® | II | 1 | NCT07406633 |
| PropranololHemangeol®, Innopran Xl® | II | 1 | NCT06775080 |
| RegorafenibRegorafinib, BAY73-4506 | II | 1 | NCT06099821 |
| RepotrectinibAugtyro® | I–II | 1 | NCT03093116 |
| FulvestrantCligavyx®, Faslodex® | I | 1 | NCT05238922 |
Sorted by most advanced phase and number of active trials. Showing 15 of 18 drugs.
All 37 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Colorectal neoplasm 534 drugs
- Pancreatic neoplasm 395 drugs
- Stomach neoplasm 340 drugs
- Hepatocellular carcinoma 266 drugs
- Non-small-cell lung carcinoma 726 drugs
- Esophageal neoplasm 191 drugs
- Esophageal squamous cell carcinoma 115 drugs
- Metastasis 493 drugs
- Rectal neoplasm 131 drugs
- Colonic neoplasm 157 drugs
- Biliary tract neoplasm 139 drugs
- Ovarian neoplasm 411 drugs
Broader categories
- Neoplasm 671 drugs
- Digestive System Diseases 36 drugs
- Gastrointestinal disease 22 drugs
- Gastrointestinal neoplasm 80 drugs
- Glandular and epithelial neoplasm 12 drugs
- Colonic disease 11 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D004067 “Digestive System Neoplasms”.